AI assistant
Verona Pharma plc — Director's Dealing 2022
Apr 12, 2022
30667_dirs_2022-04-12_4305abb0-4c57-49f2-92f5-dfa3e70adbbb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2022-04-08
Reporting Person: Rickard Kathleen A. (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-04-08 | Ordinary Shares | S | 112800 | $0.5885 | Disposed | 2606128 | Direct |
| 2022-04-11 | Ordinary Shares | S | 59720 | $0.5375 | Disposed | 2546408 | Direct |
Footnotes
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units.
F3: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.5625 to $0.6075. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.
F4: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.52 to $0.5585. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 4.
F5: Consists of (i) 1,916,968 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 239,621 ADSs); and (ii) 629,440 Ordinary Shares underlying 78,680 ADSs.